In previous years, the outcome of multiple phase 2 and 3 trials with oral B-cell receptor (BCR)-inhibitors in treatment-naïve and relapsed/refractory (R/R) CLL were reported. This led to the approval of these agents in the treatment of CLL. The latter resulted in a shift from intravenous chemotherapies, given for a fixed period of time to oral therapies that need to be given continuously, until progressive disease or unacceptable toxicity. Follow-up studies with these BTK inhibitors, combined with chemo-immunotherapy (CIT), with a monoclonal antibody or with the new Bcl-2 inhibitor venetoclax were presented during the 2017 annual meeting of the American Society of Hemtology (ASH). Some key messages are summarized below.
(BELG J HEMATOL 2018;9(1):22–5)